SCYX Q1 2021 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena

SCYXSCYNEXIS, Inc.

$37M

Q1 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$12M

Gross Profit

$12M100.0% margin

Operating Income

-$2M-13.2% margin

Net Income

-$5M-38.8% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$759,000

Free Cash Flow

-$959,000

Stock-Based Comp.

$398,000

Balance Sheet

Total Assets

$100M

Total Liabilities

$74M

Stockholders' Equity

$26M

Cash & Equivalents

$92M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$0	—
Gross Profit	$12M	$0	—
Operating Income	-$2M	-$12M	+87.2%
Net Income	-$5M	-$7M	+33.2%